Only One-Third of Gout Patients Receive Urate-Lowering Drugs Save
The most recent analysis of National Health and Nutrition Examination Survey [NHANES] 2007-2016) data shows the prevalence of gout to be 9.3 million in the USA.
Data from 5,467 participants from NHANES 2015-2016, finds gout in 3.9% or 9.2 million US adults. This includes 5.2% [5.9 million] of men and 2.7% [3.3 million] of women with gout.
Meoan serum urate levels were higher in men (6.0 mg/dL) thn women (4.8 mg/dL), with prevalence of hyperuricemia to be 20% in both.
The prevalences of gout and hyperuricemia is unchanged in the last decade (P for trend >0.05).
The prevalence of urate lowering therapy in gout patients was 33% during 2007-2014 and remained stable over time.
Despite a substantial population burden for gout, only one-third of gout patients are receiving ULT.